DE-109

DE-109 is an investigational, proprietary intravitreal formulation of sirolimus developed by Santen Inc. for the treatment of active, non-infectious uveitis of the posterior segment (NIU-PS). Sirolimus is a small molecule mTOR (mammalian target of rapamycin) inhibitor that functions as a non-steroidal immunomodulator. By inhibiting the mTOR pathway, DE-109 reduces intraocular inflammation while minimizing systemic exposure. It is designed as a steroid-sparing alternative to traditional corticosteroid treatments, potentially offering a lower risk of side effects such as glaucoma and cataract formation compared to corticosteroids. The drug has been evaluated in the SAKURA and LUMINA Phase III clinical trial programs.

Other names

intravitreal sirolimusIVT sirolimussirolimus